Predictors of compliance in mass drug administration for the treatment and prevention of lymphatic filariasis in Leogane, Haiti

American Journal of Tropical Medicine and Hygiene

Volumn 78, Issue 2, 2008, Pages 283-288

  Talbot, Jeffrey T ^b   Viall, Abigail ^c   Direny, Abdel ^d   De Rochars, Madsen Beau ^d   Addiss, David ^e   Streit, Thomas ^f   Mathieu, Els ^a   Lammie, Patrick J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Hopital Ste Croix ^*  (Haïti)

^e Fetzer Institute Kalamazoo   (United States)

^f UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFILARIAL AGENT; ANTIPARASITIC AGENT;

ADOLESCENT; ADULT; ARTICLE; ATTITUDE TO HEALTH; AWARENESS; ERADICATION THERAPY; FEMALE; FILARIASIS; HAITI; HUMAN; KNOWLEDGE; LOGISTIC REGRESSION ANALYSIS; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; PARASITE TRANSMISSION; PATIENT COMPLIANCE; PREDICTION; QUESTIONNAIRE; TREATMENT OUTCOME; ZOONOSIS; DEMOGRAPHY; ELEPHANTIASIS; MIDDLE AGED; RISK FACTOR; STATISTICAL MODEL; STATISTICS; TREATMENT REFUSAL;

ADOLESCENT; ADULT; ANTIPARASITIC AGENTS; DEMOGRAPHY; ELEPHANTIASIS, FILARIAL; FEMALE; HAITI; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS; TREATMENT REFUSAL;

EID: 41249090535     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2008.78.283     Document Type: Article

References (16)

1. Molyneux D, 2003. Lymphatic filariasis (elephantiasis) elimination: a public health success and development opportunity. Filaria J 2: 13.
2. World Health Organization, 2003. Global Programme to Eliminate Lymphatic Filariasis: Annual Report on Lymphatic Filariasis. Geneva: World Health Organization.
3. World Health Organization, 2001. Lymphatic filariasis. Wkly Epidemiol Rec 76: 149-156.
4. Michael D, Bundy DA, Grenfell BT, 1996. Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitology 112: 409-428.
5. Babu BV, Kar SK, 2004. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop Med Int Health 9: 702-709.
6. Ottesen EA, Duke BOL, Karam M, Behbehani K, 1997. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 75: 491-503.
7. Stolk WA, Swaminathan S, van Oortmarssen GJ, Das PK, Habbema JD, 2003. Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study. J Infect Dis 188: 1371-1381.
8. de Rochars MF, Kanjilal S, Direny AN, Radday J, Lafontant JG, Mathieu E, Rheingans RD, Haddix AC, Streit TG, Beach MJ, Addiss DG, Lammie PJ, 2005. The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration. Am J Trop Med Hyg 73: 888-894.
9. Mathieu E, Direny AN, de Rochars MB, Streit TG, Addiss DG, Lammie PJ, 2006. Participation in three consecutive mass drug administrations in Leogane, Haiti. Am J Trop Med Hyg 11: 862-868.
10. Pichon G, 2002. Limitation and facilitation in the vectors and other aspects of the dynamics of filarial transmission: the need for vector control against Anopheles-transmitted filariasis. Ann Trop Med Parasitol 96: S143-S153.
11. Esterre P, Plichart C, Sechan Y, Nguen L, 2001. The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: the Maupiti cohort. Trop Med Int Health 6: 190-195.
12. Mathieu E, Lammie PJ, Radday J, Beach MJ, Streit T, Wendt J, Addiss DG, 2004. Factors associated with participation in a campaign of mass treatment against lymphatic filariasis in Leogane, Haiti. Ann Trop Med Parasitol 98: 703-714.
13. Ramaiah KD, Das PK, Appavoo NC, Ramu K, Augustin DJ, Vijay Kurnar KN, Chandrakala AV, 2000. A program to eliminate lymphatic filariasis in Tamil Nadu state, India compliance with annual single-dose DEC mass treatment and some related operational aspects. Trop Med Int Health 5: 842-847.
14. de Rochars M, Direny AN, Roberts JM, Addiss DG, Radday J, Beach MJ, Streit TG, Dardith D, Lafontant JG, Lammie PJ, 2004. Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs. Am J Trop Med Hyg 71: 466-470.
15. Brady MA, Hooper PJ, Ottesen EA. 2006. Projected benefits from integrating NTD programs in sub-Saharan Africa. Trends Parasitol 22: 285-291.
16. World Health Organization, 2006. Preventive Chemotherapy in Human Helminthiasis: Coordinated Use of Anthelminthic Drugs in Control Interventions; A Manual for Health Professionals and Programme Managers. Geneva: World Health Organization.